1e
19
1
49
2
2
18
1b
1d
18
37
59
1d
2 29
1d
25
Sunita D. Nasta, MD, FACP
78
59
Professor of Clinical Medicine (Hematology-Oncology)
28
76
3
5f
Attending Physician, Hospital of the University of Pennsylvania
76
Chair, Clinical Trials Scientific Research Monitoring Committee
79
Chair, Hospital University of Pennsylvania Credentialing Committee
5d
Lymphoma Section Chief, Division of Hem/Onc
18
Department of Medicine
7
11
Department: Medicine
4
1
b
1d
46
Contact information
4d
4
3
3
3
2
4
b
1f
4d
Division of Hematology Oncology
2d Perelman Center for Advanced Medicine
22 12th Floor, South Pavilion
16 Office #12-159
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
26
2d Perelman Center for Advanced Medicine
22 12th Floor, South Pavilion
16 Office #12-159
3e 3400 Civic Center Boulevard
Philadelphia, PA 19104
30
Office: 215-662-3933
32 Fax: 215-615-5887
24
f
32 Fax: 215-615-5887
24
13
Education:
21 7 BS 26 (Microbiology & Immunology) c
27 Stanford University, Palo Alto, CA 16 , 1991.
21 7 MD c
42 Medical College of Virginia, Richmond, VA, 1995.
c
3
3
3
3
8b
Permanent link21 7 BS 26 (Microbiology & Immunology) c
27 Stanford University, Palo Alto, CA 16 , 1991.
21 7 MD c
42 Medical College of Virginia, Richmond, VA, 1995.
c
2 29
21
1e
1d
24
5e
2b Clinical trials in Castleman Diseaes
65
50 2. Bone Marrow and Stem Cell Transplantation, autologous and allogeneic.
96 3. Special interest in treating patients with aggressive non-Hodgkin's lymphoma, lymphoma in the elderly and lymphoma in the pregnant patient.
70 4. Special interest in the long-term follow-up of patients with Hodgkin's lymphoma and survivors issues.
3c 5. Management of patients with histiocytic disorders
38 6. Management of patients with Castleman disease.
1a 29
27
Description of Research Expertise
4f Clinical trials in non-Hodgkin's lymphoma, phase I, II and III2b Clinical trials in Castleman Diseaes
65
Description of Clinical Expertise
dc 1.Management of patients with Non-Hodgkin's lymphoma, Hodgkin's Lymphoma, multiple myeloma, acute and chronic leukemias with standard therapy as well as clinical experimental therapies using new agents.50 2. Bone Marrow and Stem Cell Transplantation, autologous and allogeneic.
96 3. Special interest in treating patients with aggressive non-Hodgkin's lymphoma, lymphoma in the elderly and lymphoma in the pregnant patient.
70 4. Special interest in the long-term follow-up of patients with Hodgkin's lymphoma and survivors issues.
3c 5. Management of patients with histiocytic disorders
38 6. Management of patients with Castleman disease.
1a 29
23
140 Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT.: Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma. 2 3d Leukemia 40(3): 694-697, March 2026.
ec Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD.: Methotrexate-associated Peripheral Neuropathy on 18 F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. 2 43 Clin Nucl Med. 51(2): e144-e146, Feb 2026.
11f Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M.: Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma. 2 42 Int J Part Ther. 19: 101304, Feb 7 2026.
2da Carrie Thompson 1, Marek Trněný 2, Franck Morschhauser 3, Gilles Salles 4, Patrick M Reagan 5, Mark Hertzberg 6, Huilai Zhang 7, Catherine Thieblemont 8, Bei Hu 9, Gustavo Fonseca 10, Won Seog Kim 11, Maurizio Martelli 12, Amitkumar Mehta 13, Avrita Singh 14, Mark Yan 15, Jamie Hirata 14, Matthew Sugidono 14, Calvin Lee 14, Jeff P Sharman 16, Neha Mehta-Shah 17, Christopher R Flowers 18, Hervé Tilly 19, Neil Chua 20, René-Olivier Casasnovas 21, Fiona Miall 22, Tae Min Kim 23, Xavier Cheng-Hong Tsai 24, Sunita Nasta 25, Seung Tae Lee 26, Jonathan W Friedberg 5: PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study 2 2 31 Blood 147(3): 254-265, Jan 15 2026 Notes: 14
148 Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. 6e JAMA Dermatol. 161(6): e250251, Jun 2025 Notes: doi: 10.1001/jamadermatol.2025.0251.
eb Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD.: Methotrexate-associated Peripheral Neuropathy on 18F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. 7d Clin Nucl Med. Page: Online ahead of print. Apr 18 2025 Notes: doi: 10.1097/RLU.0000000000005899.
d2 Potluri VS, Zhang S, Schaubel DE, Shaikhouni S, Blumberg EA, Nasta SD, Bloom RD, Cruz-Peralta M, Mehta RB, Lavu NR, Getachew B, Tandukar S, Reese PP, Puttarajappa CM. 106 : The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation : A Retrospective Cohort Study. Ann Intern Med. 178(2): 157-166, Feb 2025 Notes: doi: 10.7326/ANNALS-24-00165. Online ahead of print. 1a PMID:
1d9 Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY.: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. 2 40 Blood Adv 9(23): 5954-5964, Dec 9 2025.
25d Stefan Barta, Stephen Schuster, Jakub Svoboda, Jordan Carter, Elise Chong, Daniel Landsburg, Sunita Nasta, Ruchi Patel, Joseph Fraietta, Colin Thomas, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Siciliano, Marco Ruella, Rosemary Mazanet: CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 2025 Notes: "Poster Presentation"
2c
7
1d
1f
Selected Publications
1ea Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL.: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. 2 42 Blood Adv. 10(7): 2441-2451, April 2026.140 Landsburg DJ, Musoke N, Gentile C, Brooks TR, Nasta SD, Barta SK, Carter JS, Chong EA, Svoboda J, Schuster SJ, Thomas CJ, Tomasulo EB, Cook MR, Morrissette JJD, Caimi PF, Hill BT.: Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma. 2 3d Leukemia 40(3): 694-697, March 2026.
ec Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD.: Methotrexate-associated Peripheral Neuropathy on 18 F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. 2 43 Clin Nucl Med. 51(2): e144-e146, Feb 2026.
11f Jiang C, Hoover T, Baron J, Han X, Li B, Gao Y, Kim M, Hubbeling H, Chong EA, Carter J, Svoboda J, Schuster SJ, Landsburg DJ, Nasta SD, Plastaras J, LaRiviere M.: Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma. 2 42 Int J Part Ther. 19: 101304, Feb 7 2026.
2da Carrie Thompson 1, Marek Trněný 2, Franck Morschhauser 3, Gilles Salles 4, Patrick M Reagan 5, Mark Hertzberg 6, Huilai Zhang 7, Catherine Thieblemont 8, Bei Hu 9, Gustavo Fonseca 10, Won Seog Kim 11, Maurizio Martelli 12, Amitkumar Mehta 13, Avrita Singh 14, Mark Yan 15, Jamie Hirata 14, Matthew Sugidono 14, Calvin Lee 14, Jeff P Sharman 16, Neha Mehta-Shah 17, Christopher R Flowers 18, Hervé Tilly 19, Neil Chua 20, René-Olivier Casasnovas 21, Fiona Miall 22, Tae Min Kim 23, Xavier Cheng-Hong Tsai 24, Sunita Nasta 25, Seung Tae Lee 26, Jonathan W Friedberg 5: PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study 2 2 31 Blood 147(3): 254-265, Jan 15 2026 Notes: 14
148 Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. 6e JAMA Dermatol. 161(6): e250251, Jun 2025 Notes: doi: 10.1001/jamadermatol.2025.0251.
eb Ward RE, Dave N, Pai EL, Colbourn R, Banihashemi A, Nasta SD, Babatunde VD.: Methotrexate-associated Peripheral Neuropathy on 18F-FDG PET/CT and MRI Masquerading as Neurolymphomatosis. 7d Clin Nucl Med. Page: Online ahead of print. Apr 18 2025 Notes: doi: 10.1097/RLU.0000000000005899.
d2 Potluri VS, Zhang S, Schaubel DE, Shaikhouni S, Blumberg EA, Nasta SD, Bloom RD, Cruz-Peralta M, Mehta RB, Lavu NR, Getachew B, Tandukar S, Reese PP, Puttarajappa CM. 106 : The Association of Epstein-Barr Virus Donor and Recipient Serostatus With Outcomes After Kidney Transplantation : A Retrospective Cohort Study. Ann Intern Med. 178(2): 157-166, Feb 2025 Notes: doi: 10.7326/ANNALS-24-00165. Online ahead of print. 1a PMID:
1d9 Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY.: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. 2 40 Blood Adv 9(23): 5954-5964, Dec 9 2025.
25d Stefan Barta, Stephen Schuster, Jakub Svoboda, Jordan Carter, Elise Chong, Daniel Landsburg, Sunita Nasta, Ruchi Patel, Joseph Fraietta, Colin Thomas, Aditya Nimmagadda, Lavanya Peddada, Adam Snook, Nicholas Siciliano, Marco Ruella, Rosemary Mazanet: CD5-deleted chimeric antigen receptor cells (Senza5 CART5) to enhance immunotherapy against T-cell non-Hodgkin lymphoma: A first-in-human phase I clinical trial (NCT06420089. American Society of Clinical Oncology Annual Meeting, Chicago, IL. June 2025 Notes: "Poster Presentation"
2c